Healthy Skepticism Library item: 9143

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Wechsler J.
Washington report: drug wars: battles over generics and prices
Pharmaceutical Technology 1996 Jan; 20:16, 18, 20, 22, 26, 28, 30, 32

Abstract:

The recent conflict concerning patent terms and infringement between generic drug manufacturers and innovator companies is discussed, including provisions of the General Agreement on Tariffs and Trade (GATT) and the Drug Price Competition and Patent Term Restoration Act of 1984 (Waxman-Hatch Act). It was noted that rising research and development costs and managed health care, reduced prescription drug prices, and expanded generic competition have made it increasingly difficult for innovators to recoup their investments in new drug research. Efforts to improve relations with pharmacists are also discussed.